Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Blood (2012) 120 (21): 4599.

https://doi.org/10.1182/blood.V120.21.4599.4599

Published: 2012

Journal Articles

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Miguel Alcoceba, Elena Sebastián, Ana Balanzategui, Luis Marín, Santiago Montes-Moreno, Teresa Flores, Noemí Puig, M. Eugenia Sarasquete, M. Carmen Chillón, Cristina Jiménez, Rocío Corral, Eva González-Barca, M. Dolores Caballero, Jesús F. San Miguel, Ramón García-Sanz, Marcos González

Blood (2012) 120 (21): 1589.

https://doi.org/10.1182/blood.V120.21.1589.1589

Published: 2012

Journal Articles

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Blood (2012) 120 (21): 3142.

https://doi.org/10.1182/blood.V120.21.3142.3142

Published: 2012

Journal Articles

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Pau Abrisqueta, MD, Neus Villamor, MD, PhD, María José Terol, MD, PhD, Eva González-Barca, MD, PhD, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose Antonio García-Marco, MD, PhD, Yolanda González, MD, Felix Carbonell, MD, PhD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, MD, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD, Francesc Bosch, MD, PhD

Blood (2012) 120 (21): 3930.

https://doi.org/10.1182/blood.V120.21.3930.3930

Published: 2012

Journal Articles

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Blood (2012) 120 (21): 2672.

https://doi.org/10.1182/blood.V120.21.2672.2672

Published: 2012

Journal Articles

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Blood (2012) 120 (21): 2680.

https://doi.org/10.1182/blood.V120.21.2680.2680

Published: 2012

Journal Articles

Long-Term Follow-up of Patients with HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Phase II Study with Rituximab and CHOP (R-CHOP)

Josep-Maria Ribera, MD, PhD, Mireia Morgades, Albert Oriol, Eva González-Barca, MD, Pilar Miralles, Armando Lopez-Guillermo, Santiago Gardella, Andrés López, Eugènia Abella, Blanca Xicoy, MD, Marta Garcia, Evarist Feliu, MD, PhD

Blood (2011) 118 (21): 4980.

https://doi.org/10.1182/blood.V118.21.4980.4980

Published: 2011

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Francesc Bosch, MD, PhD, Pau Abrisqueta, Neus Villamor, MD. PhD, María José Terol, MD, PhD, Eva González-Barca, MD, Marcos González, MD, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A. Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD. PhD

Blood (2011) 118 (21): 293.

https://doi.org/10.1182/blood.V118.21.293.293

Published: 2011

Journal Articles

Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy

Blood (2011) 118 (21): 2664.

https://doi.org/10.1182/blood.V118.21.2664.2664

Published: 2011

Journal Articles

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Blood (2011) 118 (21): 3654.

https://doi.org/10.1182/blood.V118.21.3654.3654

Published: 2011

Journal Articles

Impact of Rituximab-Based Therapy After Histological Transformation on High-Dose Therapy and Autologous Stem Cell Transplantation in Follicular Transformed Lymphomas

Jose Manuel Calvo-Villas, Alejandro Martín, Carlos Panizo, MD, Juan Manuel Sancho, Alba Redondo, José David González-Sanmiguel, Blanca Sanchez Gonzalez, MD, Maria José Requena, Eva González-Barca, MD, María José Rodríguez-Salazar, Nerea Castro, Viviana Paredes, Jorge Gayoso, Dolores Caballero, MD

Blood (2011) 118 (21): 4478.

https://doi.org/10.1182/blood.V118.21.4478.4478

Published: 2011

Journal Articles

AICAR Induces Apoptosis In B Lymphocytes From Balb/c Mice and Its Effect In Chronic Lymphocytic Leukemia Cells Is Synergic or Additive with Current Chemotherapy

Diana M González-Gironès, Antonio F Santidrián, Daniel Iglesias-Serret, Ana M Cosialls, Alba Pérez-Perarnau, Camila Rubio-Patiño, Mercè de Frias, Alberto Fernandez de Sevilla, MD, PhD, Eva González-Barca, Esmeralda de la Banda, Gabriel Pons, Clara Campàs, Joan Gil

Blood (2010) 116 (21): 1815.

https://doi.org/10.1182/blood.V116.21.1815.1815

Published: 2010

Journal Articles

Liver Infiltration In Splenic Marginal Zone Lymphoma: Prevalence and Prognostic Implication

Eva Domingo-Domenech, Vicente Romagosa, Eva González-Barca, Marta Rodriguez-Aliberas, Ana Oliveira, Esmeralda de la Banda, Santiago Mercadal, Jose Sarra, Jose Petit, Alberto Fernandez de Sevilla, MD, PhD

Blood (2010) 116 (21): 4137.

https://doi.org/10.1182/blood.V116.21.4137.4137

Published: 2010

Journal Articles

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Francesc Bosch, MD, PhD, Neus Villamor, Pau Abrisqueta, MD, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, MD, PhD, Yolanda Gonzalez, Felix Carbonell, MD, Secundino Ferrer, Encarna Monzo, MD, Isidro Jarque, MD, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat, MD

Blood (2010) 116 (21): 1382.

https://doi.org/10.1182/blood.V116.21.1382.1382

Published: 2010

Journal Articles

Acadesine for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase I/II Study

Eric Van den Neste, Bruno Cazin, Ann Janssens, M.D., Eva González-Barca, María José Terol, Vincent Levy, Jaime Pérez de Oteyza, Pierre Zachee, Andrew Saunders, Mercè de Frias, Clara Campàs

Blood (2010) 116 (21): 4625.

https://doi.org/10.1182/blood.V116.21.4625.4625

Published: 2010

Journal Articles

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Blood (2010) 116 (21): 2448.

https://doi.org/10.1182/blood.V116.21.2448.2448

Published: 2010

Journal Articles

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.

Eva González-Barca, Miguel Canales, MD, PhD, María Jesús Vidal, Albert Oriol, Antonio Salar, Joan Bargay, Montse Cortés, Juan Coya, José Francisco Tomás, Andrés López, José Javier Sánchez, Eva Donato, Andrés Llorente, Secundino Ferrer, Dolores Caballero

Blood (2010) 116 (21): 2793.

https://doi.org/10.1182/blood.V116.21.2793.2793

Published: 2010

Journal Articles

Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.

Adolfo de la Fuente, Sr., Antonio Salar, MD, PhD, Carlos Panizo, MD, Belen Navarro, Sr., Teresa Olave, María Jesus Peñarrubia, MD, JoaquÃn Herrero, MD, PhD, Jose Francisco Tomas, Miguel Canales, Eva González-Barca

Blood (2009) 114 (22): 1663.

https://doi.org/10.1182/blood.V114.22.1663.1663

Published: 2009

Journal Articles

AICAR Induces Apoptosis in Chronic Lymphocytic Leukemia Cells through the Mitochondrial Pathway and Independently of p53 Pathway and AMPK Activation.

Joan Gil, PhD, Antonio F Santidrián, PhD, Diana M González-Gironès, PhD, Daniel Iglesias-Serret, PhD, Llorenç Coll-Mulet, PhD, Ana M Cosialls, PhD, Mercè de Frias, PhD, Clara Campàs, PhD, Eva González-Barca, MD, PhD, Esther Alonso, MD, Alberto Fernandez de Sevilla, MD, PhD, Benoit Viollet, PhD, Gabriel Pons, MD, PhD

Blood (2009) 114 (22): 4819.

https://doi.org/10.1182/blood.V114.22.4819.4819

Published: 2009

Journal Articles

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Blanca Espinet, PhD, Salaverría Itziar, PhD, Sílvia Beà, PhD, Neus Ruiz-Xivillé, Olga Balagué, MD, Marta Salido, Dolors Costa, PhD, Ana E Rodriguez, Juan LuíS. García, PhD, JesúS. M.ª Hernández-Rivas, MD, PhD, M.ª José Calasanz, PhD, Ana M Ferrer, MD, PhD, Antonio Salar, MD, PhD, Ana Carrió, PhD, Natividad Polo, Jose Antonio García-Marco, MD, PhD, Alicia Domingo, MD, Eva González-Barca, MD, PhD, Vicenç Romagosa, MD, Isabel Marugán, Armando López-Guillermo, MD, PhD, Fuensanta Millá, MD, José Luís Mate, MD, PhD, Elisa Luño, MD, PhD, Carmen Sanzo, MD, PhD, Rosa Collado, MD, PhD, Isabel Oliver, Sebastià Monzó, MD, Antonio Palacín, MD, Teresa González, Francesc Sant, MD, Ramon Salinas, MD, PhD, Mª Teresa Ardanaz, MD, Llorenç Font, MD, PhD, Lourdes Escoda, MD, Lourdes Florensa, MD, PhD, Elias Campo, MD, PhD, Sergi Serrano, MD, PhD, Francesc Solé, PhD

Blood (2008) 112 (11): 1765.

https://doi.org/10.1182/blood.V112.11.1765.1765

Published: 2008

NARROW

Assessment of Minimal Residual Disease Levels in B-CLL After Front-Line Treatment with FC-R and Rituximab Maintenance

Preferential Acquision of N-Glycosylation Sites in the VDJ Region in Germinal Center B-Cell-Like Difusse Large B-Cell Lymphoma

Efficacy of Autologous Stem-Cell Transplantation in Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma in the Rituximab Era. A Multicenter Geltamo Study.

Prognostic Impact of the MRD Status After Induction Treatment with Rituximab Plus Fludarabine, Cyclophosphamide and Mitoxantrone (R-FCM) in Patients with Chronic Lymphocytic Leukemia Receiving Rituximab Maintenance Therapy

Risk Adapted-High Dose Therapies Modulate the Impact of Biological Classification in Diffuse Large B Cell Lymphoma Prognosis. Analysis of Biological Markers in Patients From Clinical Trials in Geltamo and Gotel Spanish Collaborative Groups.

Relationship Between HLA Class I and II Polymorphisms with Susceptibility and Clinical Outcome in Diffuse Large B-Cell Lymphoma.

Long-Term Follow-up of Patients with HIV-Related Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Phase II Study with Rituximab and CHOP (R-CHOP)

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)

Prognostic Value of cMYC Gene Abnormalities in Diffuse Large B Cell Lymphoma Treated with Chemo-Immunotherapy

Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),

Impact of Rituximab-Based Therapy After Histological Transformation on High-Dose Therapy and Autologous Stem Cell Transplantation in Follicular Transformed Lymphomas

AICAR Induces Apoptosis In B Lymphocytes From Balb/c Mice and Its Effect In Chronic Lymphocytic Leukemia Cells Is Synergic or Additive with Current Chemotherapy

Liver Infiltration In Splenic Marginal Zone Lymphoma: Prevalence and Prognostic Implication

Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).

Acadesine for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase I/II Study

Rituximab Maintenance Treatment After Combined Fludarabine, Cyclophosphamide and Rituximab In Previously Untreated Patients with Progressive B-Cell Chronic Lymphocytic Leukemia (CLL): Interim Analysis of An Ongoing Phase II Multicenter Trial On Behalf of the Spanish CLL Study Group (GELLC)

Predictive Value for Event-Free Survival of Interim 18F-FDG-PET In Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with 6 Cycles of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim as First-Line Treatment: An Open-Label Clinical Trial In Spain.

Efficacy and Safety of Liposomal Cytarabine as Intrathecal Prophylaxis in Patients with Diffuse Large B Cell Lymphoma at High Risk of CNS Involvement: A Multicentric Study Including 80 Patients in Spain.

AICAR Induces Apoptosis in Chronic Lymphocytic Leukemia Cells through the Mitochondrial Pathway and Independently of p53 Pathway and AMPK Activation.

Analysis of Cytogenetic Abnormalities and Their Prognostic Impact in a Series of 145 Mantle Cell Lymphoma Cases with An Abnormal Karyotype.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only